Midazolam and Rufinamide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Midazolam (midazolam) and Rufinamide (rufinamide). Common drug interactions include multiple-drug resistance among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Midazolam and Rufinamide. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Midazolam?

Midazolam has active ingredients of midazolam. eHealthMe is studying from 11,246 Midazolam users. Check the latest studies of Midazolam.

What is Rufinamide?

Rufinamide has active ingredients of rufinamide. eHealthMe is studying from 946 Rufinamide users. Check the latest studies of Rufinamide.

On Jul, 11, 2026

21 people who take Midazolam and Rufinamide together, and have interactions are studied.

Midazolam and Rufinamide drug interactions.

What are the common drug interactions of Midazolam and Rufinamide, by gender? *:

female:

Multiple-drug resistance
Rash
Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
Brain neoplasm (tumour of brain)
Disease recurrence
Drug ineffective
Dyspnoea exertional (breathlessness or shortness of breath)
Febrile convulsion (a convulsion associated with a significant rise in body temperature)
Gait disturbance
Heart rate increased

male:

Drug ineffective
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Gastrointestinal pain
Hospitalisation
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Irritability
Multiple-drug resistance
Muscular weakness (muscle weakness)
Petit mal epilepsy (absence seizure)

What are the common drug interactions of Midazolam and Rufinamide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Multiple-drug resistance
Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure)
Drug ineffective
Liver disorder (liver diseases)

10-19:

Drug ineffective
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Infusion site pain
Multiple-drug resistance
Abdominal pain
Aggression
Discomfort
Disease recurrence
Drug resistance (reduction in effectiveness of a drug)
Dry skin

20-29:

Dysphagia (a condition in which swallowing is difficult or painful)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)

30-39:

Rash
Skin warm
Dyspnoea exertional (breathlessness or shortness of breath)
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Lymphadenopathy (disease or enlargement of lymph nodes)
Malaise (a feeling of general discomfort or uneasiness)
Neck pain
Pyrexia (fever)
Rash erythematous (redness of the skin)

40-49:

n/a

50-59:

n/a

60+:

Confusional state

What are the existing conditions these people have? *

Seizures (abnormal excessive or synchronous neuronal activity in the brain): 9 people, 42.86%
Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 6 people, 28.57%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 5 people, 23.81%
Sedation: 2 people, 9.52%
Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Midazolam and Rufinamide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously